Most head and neck squamous cell carcinoma (HNSCC) cases are diagnosed late, with an increased risk of recurrence and distant metastasis. In recent years, there has been a surge in the development of ...
Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...
Head and neck squamous cell carcinoma (HNSCC) remains a globally prevalent malignancy with high morbidity and mortality. Despite therapeutic advances, patient outcomes are hindered by tumor ...
Metabolic dysregulation is increasingly recognized as a driver of tumor progression, yet its specific role in head and neck squamous cell carcinoma (HNSCC) remains poorly characterized. This study ...
Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...
A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck. This is an ASCO Meeting Abstract from ...
New atlas that charts tumor cell diversity could guide personalized therapy for head and neck cancer
Head and neck squamous cell carcinomas (HNSCC) are the seventh-most prevalent form of cancer and are associated with human papilloma virus infection (HPV-positive) or with tobacco and alcohol use (HPV ...
VMPLNew Delhi [India], June 23: In one of oncology’s most anatomically complex regions, the difference between an accurate treatment plan and an imprecise one can be measured in millimetres, and felt ...
Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)—a cancer which is notoriously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results